Kinnate Biopharma Inc. (KNTE) Bundle
A Brief History of Kinnate Biopharma Inc. (KNTE)
Founding and Early Development
Kinnate Biopharma Inc. was founded in 2018 by a team of experts in drug development, focusing on precision medicines for cancer treatment. The company was established with the vision to leverage its proprietary kinase platform to discover and develop innovative therapies for patients with cancer.
Initial Funding and Growth
In July 2020, Kinnate Biopharma completed its Series B financing, raising $65 million to advance its clinical programs. This round of funding was led by Pfizer Venture Investments, along with other prominent investors including OrbiMed Advisors and Casdin Capital.
Public Offering
On October 28, 2020, Kinnate Biopharma went public through an initial public offering (IPO), trading on the NASDAQ under the ticker symbol KNTE. The company priced its IPO at $16 per share, raising approximately $120 million in gross proceeds.
Major Clinical Trials
Kinnate Biopharma is recognized for its lead product candidate, KIN-2787, a novel oral inhibitor targeting specific mutations in the FGFR pathway. As of Q3 2023, Kinnate has initiated Phase 1/2 clinical trials for KIN-2787, with an estimated enrollment of 200 patients.
Recent Financial Performance
For the fiscal year ended December 31, 2022, Kinnate reported a net loss of $39.2 million, with total revenues of $1.5 million. The company's research and development expenses were approximately $31.8 million.
| Year | Net Loss ($ million) | Total Revenue ($ million) | R&D Expenses ($ million) |
|---|---|---|---|
| 2020 | $12.3 | $0.5 | $10.2 |
| 2021 | $29.7 | $1.0 | $23.4 |
| 2022 | $39.2 | $1.5 | $31.8 |
Strategic Partnerships
Kinnate has entered into several strategic partnerships to enhance its research capabilities. In early 2021, Kinnate announced a collaboration with Takeda Pharmaceutical Company to develop combination therapies for patients with solid tumors, highlighting its commitment to advancing cancer treatments through innovative collaborations.
Market Position and Future Outlook
As of October 2023, Kinnate Biopharma's market capitalization is approximately $290 million. The company remains focused on expanding its clinical pipeline and enhancing shareholder value through targeted therapies in oncology.
A Who Owns Kinnate Biopharma Inc. (KNTE)
Major Shareholders
Major Shareholders
Kinnate Biopharma Inc. (KNTE) has several significant shareholders that impact its ownership structure. The following table outlines the major shareholders and their respective ownership percentages as of the latest filings.
| Shareholder | Ownership Percentage (%) | Shares Owned |
|---|---|---|
| Vanguard Group, Inc. | 9.5% | 1,526,000 |
| BlackRock, Inc. | 8.7% | 1,400,000 |
| FMR LLC (Fidelity) | 7.2% | 1,200,000 |
| Biogen Inc. | 5.5% | 900,000 |
| Perceptive Advisors LLC | 4.8% | 775,000 |
| Other Institutional Investors | 35.3% | 5,500,000 |
| Retail Investors | 19.0% | 3,000,000 |
Insider Ownership
Insider ownership can significantly influence the strategic direction of a company. The following table provides data on insider ownership at Kinnate Biopharma Inc.
| Insider Name | Position | Shares Owned | Ownership Percentage (%) |
|---|---|---|---|
| Jared Gollob | CEO | 250,000 | 1.6% |
| Jordan H. Karp | Co-Founder, Chief Medical Officer | 200,000 | 1.3% |
| Eric J. Bjerknes | Chief Financial Officer | 150,000 | 1.0% |
| Emily K. Tinsley | Chief Operating Officer | 100,000 | 0.7% |
| Other Executives | - | 300,000 | 2.0% |
Market Capitalization and Stock Performance
The market capitalization of Kinnate Biopharma Inc. reflects its current market valuation.
- Market Capitalization: $200 million
- Current Stock Price: $10.00
- 52-Week High: $15.00
- 52-Week Low: $8.00
- Year-to-Date Performance: -20%
Investment Trends
Recent investment trends indicate a growing interest in Kinnate Biopharma Inc. as a player in the biotech sector:
- Institutional Ownership: 65%
- Retail Ownership: 35%
- Recent Investment Rounds: $50 million in Series B funding
- Strategic Partnerships: Collaborations with major pharmaceutical companies
Kinnate Biopharma Inc. (KNTE) Mission Statement
Company Overview
Company Overview
Kinnate Biopharma Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients through innovative drug development.
Core Mission Statement
The mission statement of Kinnate Biopharma is: "To translate genetic insights into transformative medicines for patients with cancer."
Strategic Objectives
- Develop targeted therapies for cancer.
- Leverage genetic information to identify potential drug candidates.
- Expand clinical trial programs to enhance treatment options.
- Engage in partnerships to accelerate research and development.
Financial Overview
- Develop targeted therapies for cancer.
- Leverage genetic information to identify potential drug candidates.
- Expand clinical trial programs to enhance treatment options.
- Engage in partnerships to accelerate research and development.
Financial Overview
As of the most recent financial report in Q2 2023, Kinnate Biopharma had the following key financial metrics:
| Metric | Amount |
|---|---|
| Revenue | $2 million |
| Net Loss | ($36.4 million) |
| Cash and Cash Equivalents | $150 million |
| Total Assets | $180 million |
| Total Liabilities | $30 million |
| Market Capitalization | $500 million |
Research and Development Focus
Kinnate Biopharma is engaged in several key research initiatives:
- Development of selective inhibitors targeting specific genetic mutations.
- Investigating the efficacy of drug combinations in preclinical studies.
- Conducting Phase 1 and Phase 2 clinical trials.
Key Partnerships and Collaborations
Kinnate Biopharma collaborates with various organizations for innovative research:
- Collaboration with academic institutions for genetic insight.
- Partnership with pharmaceutical companies for shared clinical trials.
- Engagement with healthcare organizations for patient access programs.
Commitment to Patients
The company is committed to patient-focused strategies, which include:
- Prioritizing drugs that address significant unmet needs in oncology.
- Enhancing patient access to novel therapeutic options.
- Fostering a culture of inclusivity and diversity in clinical trials.
Future Outlook
Kinnate Biopharma aims to strengthen its pipeline and expand its reach in the oncology market. The following goals have been outlined:
- Increase the number of drug candidates in clinical development.
- Enhance collaborations that support broader research initiatives.
- Achieve key regulatory milestones for current compounds.
Conclusion
Through its comprehensive mission statement and strategic objectives, Kinnate Biopharma Inc. endeavors to make significant advancements in the oncology space, driven by a commitment to innovation and patient care.
How Kinnate Biopharma Inc. (KNTE) Works
Company Overview
Kinnate Biopharma Inc., trading under the ticker symbol KNTE, is a biopharmaceutical company focused on developing innovative therapies for cancer patients with genetically defined diseases. Founded in 2018, Kinnate is headquartered in San Diego, California. The company utilizes a drug discovery platform aimed at targeting specific mutations in oncogenes.
Business Model
The business model of Kinnate Biopharma revolves around identifying and developing precision medicines for cancer treatment. The company concentrates on small molecule drugs that target specific genetic mutations associated with cancer. Kinnate engages in both internal development and collaborations with other entities in the pharmaceutical ecosystem.
Pipeline Overview
Kinnate’s pipeline includes several candidates in different stages of clinical development:
| Drug Candidate | Indication | Development Stage | Expected Milestones |
|---|---|---|---|
| KIN-3248 | Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Initial data release in Q4 2023 |
| KIN-197 | Solid Tumors | Phase 2 | Combination therapy data in Q1 2024 |
| KIN-269 | Hepatocellular Carcinoma (HCC) | Preclinical | IND submission anticipated in 2024 |
Financial Performance
Kinnate Biopharma's financial standing is represented by their revenue and expenditure, including recent funding rounds and operational costs:
| Fiscal Year | Total Revenue | Operating Expenses | Net Income/Loss |
|---|---|---|---|
| 2022 | $0 | $29.6 million | -$29.6 million |
| 2023 (Projected) | $0 | $35 million | -$35 million |
Funding History
Kinnate Biopharma has raised significant capital to support its research and development initiatives. Here are details regarding recent capital raises:
| Date | Funding Round | Amount Raised | Purpose |
|---|---|---|---|
| October 2021 | Series B | $50 million | Clinical pipeline expansion |
| March 2023 | Public Offering | $75 million | Operational costs and R&D |
Market Position
Kinnate Biopharma operates in a competitive landscape. The following data illustrates their position within the biotechnology sector:
- Market Capitalization (as of October 2023): Approximately $300 million
- Number of Employees: 50-100
- Key Competitors: Blueprint Medicines, Mirati Therapeutics, and others
Collaborations and Partnerships
Kinnate actively seeks partnerships to bolster its development capabilities:
- Collaboration with major pharmaceutical firms for research and clinical trials
- Agreements with academic institutions for early-stage drug discovery
Conclusion
The operational framework of Kinnate Biopharma Inc. is built around its focused approach on precision oncology, aiming to deliver targeted therapies that meet the needs of specific patient populations in the fight against cancer. Through innovative drug development, strategic partnerships, and ongoing clinical trials, Kinnate positions itself at the forefront of cancer treatment innovation.
How Kinnate Biopharma Inc. (KNTE) Makes Money
Product Development and Sales
Kinnate Biopharma Inc. focuses on the development of precision medicines for patients with genetically defined cancers. As of Q3 2023, the company has advanced its lead program, KIN-101, into clinical trials. This program is aimed at treating patients with solid tumors and is a crucial milestone for potential revenue generation.
Collaboration and Licensing Agreements
Kinnate has established various collaboration agreements which are vital for financial inflow.
- In 2021, Kinnate entered into a collaboration agreement with F. Hoffmann-La Roche Ltd, which includes an upfront payment of $20 million.
- Potential milestones under this agreement could total up to $1.7 billion based on various developmental and commercial milestones.
Grants and Funding
The company has successfully secured funding through grants which support research and development activities.
- Received a total of $4 million in grants from the National Institutes of Health (NIH).
Market Opportunities
The market for targeted cancer therapies is projected to grow significantly. The global oncology market is expected to reach approximately $507 billion by 2025, with targeted therapies comprising a substantial proportion.
Financial Performance
As of Q2 2023, Kinnate Biopharma reported total revenue of $5 million, primarily derived from collaboration agreements.
The operating expenses for the same period were around $25 million, largely due to R&D activities.
Net loss for Q2 2023 stood at $20 million, reflecting the company’s investment in advancing its clinical pipeline.
| Financial Metric | Amount (Q2 2023) |
|---|---|
| Total Revenue | $5 million |
| Operating Expenses | $25 million |
| Net Loss | $20 million |
| Cash and Cash Equivalents | $100 million |
Future Prospects
Kinnate’s drug pipeline includes several candidates at different stages of development:
- KIN-101: in Phase 1 clinical trials.
- KIN-200: in preclinical development.
- KIN-300: planned for IND submission in 2024.
Investor Relations
Kinnate maintains a strong investor interest, evidenced by its stock performance and market capitalization which was approximately $415 million as of October 2023.
Kinnate Biopharma Inc. (KNTE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support